Aims: Patients with metastatic gastrointestinal stromal tumours (GIST) are treated in first line with the oral tyrosine kinase inhibitor, imatinib, until progressive disease.
| INTRODUCTION
Gastrointestinal stromal tumours (GIST) are the most common type of soft tissue sarcoma. Worldwide, the annual incidence of GIST is about 10 cases per million people, corresponding to at least 8000 new cases per year in Europe. 1, 2 Patients with metastatic or unresectable GIST receive fixed dosed imatinib as first-line treatment until progressive disease. 3, 4 When disease progression is noticed, the dose of imatinib is doubled, followed by second-line treatment with sunitinib and third-line treatment with regorafenib after each progression. Sunitinib, regorafenib and double-dosed imatinib are regarded as more toxic with worse quality of life compared to standard dosed imatinib. In its palliative intent, the goal of treatment with imatinib, sunitinib and regorafenib in patients with GIST is to improve the progression free survival, with the lowest toxicity. [5] [6] [7] Imatinib mesylate is an oral tyrosine kinase inhibitor that has been approved at fixed doses of once daily 400 mg for use in different types of cancer, e.g. BRC-Abl positive chronic myeloid leukaemia and GIST. 8, 9 However, since this drug shows large interpatient variability in pharmacokinetics sub-and supratherapeutic exposures may be encountered which could affect treatment outcome. In addition, in retrospective analyses improved efficacy was shown at plasma concentrations >1100 μg/L while more adverse events were observed at plasma concentrations >3200 μg/L.
10,11
Therefore, it is important to treat patients within the therapeutic index. Since many factors may influence the plasma exposure of imatinib, it is not possible to predict whether an individual patient will reach an adequate plasma exposure using a standard fixed dose of the drug.
Therapeutic drug monitoring (TDM) is a technique used to determine plasma exposure for certain drugs, and to adjust the dose in order to achieve plasma exposure within the therapeutic index. A study by Lankheet et al 12 shows that the use of TDM in GIST patients treated with imatinib results in 95% of the patients to achieve adequate therapeutic plasma concentrations. Additionally, TDM has been shown to improve safety and efficacy of many targeted oral anticancer drugs. 13, 14 A relationship between plasma exposure and treatment outcome has been retrospectively established for imatinib in patients with GIST, 10 supporting the rationale for the use of TDM in GIST patients treated with imatinib. While the effect of TDM to redistribute patients to adequate plasma concentrations has been proven, it is currently unknown what the financial consequences of TDM is compared with fixed dosing. While an increase in clinical efficacy may result in a reduction in costs associated with slower disease progression and less adverse events, it is unclear whether these savings weigh up to the additional costs that come with the use of increased and prolonged dosages and laboratory handling costs associated with TDM.
The aim of this study is to evaluate the cost-effectiveness of TDM in patients with metastatic/unresectable GIST treated with imatinib as first line treatment, compared with fixed dosing of imatinib.
2 | METHODS
| General considerations
To determine the possible gain of TDM over fixed dosing in GIST patients treated with imatinib, the costs and effects of both groups, What this study adds
• This paper explores the effect of TDM on quality of life gains, occurrences of adverse events, and associated costs in GIST patients treated with imatinib.
• TDM may be a cost-effective intervention for GIST patients treated with imatinib. Transition probabilities from IPF to EIPF were different for each therapeutic subgroup, based on the data from Demetri et al 10 to account for differences in progression due to the effect of the respective therapeutic groups. PFS for the supratherapeutic health-state was extrapolated beyond 42 months due to lack of data. OS data for the subtherapeutic imatinib health-state was not available, and was extrapolated based on the PFS data for this health-state. The further treatment groups of sunitinib and regorafenib were not split in therapeutic subgroups due to lack of data. Chances of adverse events occurring were determined for each treatment group. For each treatment group the most common adverse events have been used. Only severe (grade 3 or 4) adverse events have been taken into account in this model, since the costs of grade 1 and 2 adverse events are considered to be low.
| Costs
Direct drug acquisition costs were gathered from the Dutch National
Health Care Institute (www.medicijnkosten.nl, accessed October 
| Analyses
A probabilistic comparison of fixed dosing vs the TDM-guided dosing in the first line of treatment of GIST patients was performed from a Dutch health-care perspective. Additionally, sensitivity analyses were conducted in order to explore overall parameter uncertainty. Analyses were run using 5000 iterations, each stochastically sampling parameter values in the determined ranges. Beta-and γ-distributions were used for transition probabilities and costs, respectively, and plausible uncertainty was taken into account for all parameter range distributions. Results of analyses were used to estimate incremental cost-utility ratios (ICUR). Additionally, scatter-plots and costeffectiveness acceptability curves were created to graphically describe cost-effectiveness.
| Sensitivity analyses
Currently, imatinib is patented by Novartis under the name Glivec/Gleevec. This patent is set to expire in the near future, resulting in drastic changes in the pricing of this drug. Decreased generic drug costs or discounts up to 99% are possible. To determine the effect of changes in drug pricing of imatinib on the costeffectiveness of TDM, decreased drug costs of 50%, 80%, 95% and 99% were used. Other sensitivity analyses performed are variations in imatinib and BSC utility values, as well as increased costs of adverse events and BSC to determine whether or not the analyses are robust.
Discount rates of 4% and 1.5% were used for costs and QALYs, respectively, in agreement of our national guidelines for pharmacoeconomic research. 23 3 | RESULTS
| Base case
Based on our model we estimated that over a 5-year time horizon, 66% and 42% of the patients following the GIST treatment would die in the fixed dosing and TDM group, respectively ( 
| Sensitivity analyses
The 1-way sensitivity analyses for possible discounts, ranging from 50 to 99% discount, in imatinib drug prices showed a reduction in the 
| DISCUSSION
We hypothesized that TDM would result in longer time to progression and delayed costs related to second-and third-line drugs. However, TDM-guided dosing was also expected to be more expensive due to the laboratory costs made for TDM and higher doses of imatinib that need to be given in subtherapeutic patients. The question was whether the gain in health and related cost-savings would outweigh these extra costs.
Given the available data, these analyses suggest that the use of TDM provides additional clinical benefit and may be cost-effective for patients with metastatic/unresectable GIST starting with imatinib as a first line of treatment. An average ICUR of €58 758.70 per QALY gained was found. The use of TDM is shown to be cost-effective in 100% of the cases when a willingness to pay of €72 000.00 per QALY gained is used. As a reference, in the Netherlands, a maximum cost of €80 000 per QALY gained is widely used as the threshold value for cost-effectiveness in patients with highest burden of disease. 24 Using this metric, TDM can be regarded as a cost-effective intervention for use in the Netherlands, however this may not be the case for other countries with different cost-effectiveness thresholds. Ultimately, it is up to the decision-maker to decide whether ICURs are acceptable. Our sensitivity analyses on potential decreased costs of imatinib in the nearby future might support the uptake of our conclusion,
showing that ICUR will dramatically decrease with expected discounts up to 99%. This can be explained by the fact that the imatinib drug cost is the main cost-driver in this analysis, due to the additional imatinib doses given to patients to be treated within the therapeutic index.
The additional sensitivity analyses showed no large effect on the adherence from patients to all parts of the treatment is 100%. In reality, this may not the case. 26, 27 This may have resulted in an overestimation of the cost-effectiveness of TDM-guided dosing. The effect of GIST and its treatment on absence from work and associated costs were explored but ultimately not taken into account in this model due to lack of available data. Due to prolonged time to progression, a larger number of patients may be able to participate in the workforce, decreasing costs associated by absence from work, and further increasing the cost-effectiveness of TDM-guided dosing vs fixed dosing.
| CONCLUSION
This analysis suggests that TDM-guided dosing provides additional clinical benefit and may be cost-effective compared to fixed dosing in patients suffering from metastatic/unresectable GIST, using imatinib as a first line of treatment, especially when imatinib loses its patent whereby drugs costs will significantly decrease.
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